10-QPeriod: Q1 FY2010

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2010

Filed May 5, 2010For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed its Form 10-Q for the quarterly period ended March 31, 2010, reporting significant financial shifts and operational developments. The company is focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Key financial movements include a substantial increase in cash and cash equivalents and marketable securities, driven by significant financing activities, partially offset by increased operating losses and investment in property and equipment. Operationally, DexCom is advancing its product pipeline, including its SEVEN PLUS system and exploring in-hospital applications. The company faces ongoing challenges related to market acceptance, reimbursement, competition, and regulatory approvals. Despite a substantial accumulated deficit, DexCom believes its current cash position is sufficient for the next twelve months, but anticipates continued losses and potential future funding needs. The company is also actively engaged in patent litigation with Abbott Diabetes Care, Inc., which presents an ongoing risk.

Financial Highlights

5 data points
Beta

Revenue

$9.54M

36.2% Gross Margin

Net Income

-$20.27M

-212.4% Net Margin

EPS (Diluted)

$-0.10

Financial Statements
Beta
Revenue$9.54M
Gross Profit$3.46M
Operating Expenses$14.53M
Net Income-$20.27M
EPS (Basic)$-0.10

Key Highlights

  • 1Total revenue for the quarter ended March 31, 2010, was $9.5 million, a significant increase from $5.2 million in the same period of 2009, driven by product revenue growth.
  • 2Product revenue more than doubled, rising to $6.8 million from $2.7 million year-over-year, indicating growing market adoption of their continuous glucose monitoring systems.
  • 3The company reported a net loss of $20.3 million for the quarter, an increase from $13.1 million in the prior year, primarily due to a significant $7.9 million loss on debt extinguishment upon conversion of convertible debt.
  • 4Cash and cash equivalents saw a substantial increase, reaching $10.7 million by the end of the quarter, up from $3.6 million at the end of 2009, largely due to strong financing activities.
  • 5Short-term marketable securities also grew significantly to $39.2 million from $24.4 million, reflecting strategic deployment of capital.
  • 6Operating expenses, particularly Selling, General and Administrative (SG&A), increased to $9.8 million from $7.9 million, supporting revenue growth and commercialization efforts.
  • 7The company has $60 million in Convertible Senior Notes outstanding, with $54 million being exchanged for common stock in the current quarter, significantly reducing long-term debt and impacting the loss on debt extinguishment.

Frequently Asked Questions

DexCom is a medical device company focused on continuous glucose monitoring (CGM) systems. For the quarter ended March 31, 2010, the company reported a total revenue of $9.5 million, a substantial increase from $5.2 million in the same period of 2009, driven primarily by a significant rise in product revenue to $6.8 million. Despite revenue growth, the company incurred a net loss of $20.3 million, an increase from the prior year's loss of $13.1 million, impacted by a significant loss on debt extinguishment.

DexCom's financial position has strengthened in terms of liquidity. Cash and cash equivalents significantly increased to $10.7 million from $3.6 million, and short-term marketable securities grew to $39.2 million from $24.4 million. This was largely driven by financing activities, including a follow-on public offering. A significant portion of its convertible debt was exchanged for common stock, reducing the long-term debt from $45.8 million to $5.0 million and resulting in a substantial loss on extinguishment.

Operationally, DexCom is advancing its SEVEN PLUS system and exploring in-hospital applications. Key risks include the potential for market non-acceptance of their products, dependence on third-party payor reimbursement, intense competition from established medical device companies, and the ongoing patent litigation with Abbott Diabetes Care. The company also faces challenges in scaling manufacturing and obtaining regulatory approvals for new products.